Related Experiment Video
Updated: Aug 17, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Recently initiated studies: neoadjuvant treatments in the next century
1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611-2926, USA.
Abstract:
The adjuvant therapy of early breast cancer currently succeeds in eradicating micrometastatic disease in a proportion of women at risk of relapse. However, much remains to be done to improve its efficacy. Trials that are presently being conducted will determine whether increasing the dose density or dose intensity of existing agents, or altering their sequencing, will bring greater benefit. A further pressing need is for new agents with proven activity in stage IV disease, such as docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), to be assessed in the adjuvant setting. A phase II study with docetaxel was conducted in the neoadjuvant setting in stage III breast cancer patients. Preliminary results on 33 patients showed an overall response rate of 85% with neoadjuvant docetaxel and a manageable safety profile. Based on this encouraging experience and the phase II and III docetaxel single-agent and combination studies, the National Surgical Adjuvant Breast Project is investigating regimens involving docetaxel before or after surgery, and ongoing European trials are assessing the sequencing of dose-dense doxorubicin and docetaxel before surgery.
Insights
Adjuvant therapy for early breast cancer needs improvement. Docetaxel shows promise in neoadjuvant settings for stage III breast cancer, with an 85% response rate in preliminary trials.
Area of Science:
- Oncology
- Pharmacology
Background:
- Adjuvant therapy for early breast cancer aims to eliminate micrometastatic disease and prevent relapse.
- Current adjuvant treatments are effective for some but require further optimization for improved efficacy.
- There is a need to evaluate novel agents with proven efficacy in advanced disease for adjuvant settings.
Purpose of the Study:
- To assess the efficacy and safety of docetaxel in the neoadjuvant treatment of stage III breast cancer.
- To explore the potential of docetaxel as an adjuvant therapy for early breast cancer.
- To inform ongoing and future clinical trials investigating docetaxel in breast cancer treatment.
Main Methods:
- A phase II clinical study was conducted.
- Docetaxel was administered in the neoadjuvant setting to patients with stage III breast cancer.
- Preliminary results were analyzed for response rates and safety profiles.
Main Results:
- Preliminary results from 33 patients demonstrated an overall response rate of 85% with neoadjuvant docetaxel.
- The safety profile of neoadjuvant docetaxel was found to be manageable.
- These findings support further investigation of docetaxel in adjuvant and neoadjuvant breast cancer treatment.
Conclusions:
- Neoadjuvant docetaxel shows significant promise for stage III breast cancer patients.
- Docetaxel exhibits a manageable safety profile in this setting.
- The positive preliminary results warrant further investigation in larger adjuvant and neoadjuvant trials, including combinations and sequencing with other agents.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...